COLLATERAL AGREEMENT DATED AS OF JANUARY 31, 2019 AMONG EGALET CORPORATION, as Issuer, EGALET US INC., EGALET LIMITED, THE SUBSIDIARY PARTIES FROM TIME TO TIME PARTY HERETO U.S. BANK NATIONAL ASSOCIATION, as Trustee, and U.S. BANK NATIONAL...Collateral Agreement • February 1st, 2019 • Egalet Corp • Pharmaceutical preparations • New York
THIS COLLATERAL AGREEMENT (as amended, extended, renewed, restated, supplemented, waived or otherwise modified from time to time, this “Agreement”) is entered into as of January 31, 2019, by and among EGALET CORPORATION, a Delaware corporation with an address at 600 Lee Road, Suite 100, Wayne, Pennsylvania 19087 (the “Issuer”), EGALET US INC., a Delaware corporation (“Egalet US”), EGALET LIMITED, a private limited company formed under the law of England and Wales (“Egalet UK”), the other SUBSIDIARY PARTIES (as defined below) from time to time party hereto, U.S. BANK NATIONAL ASSOCIATION, in its capacity as Trustee (and its successors under the Indenture (as defined below), in such capacity, the “Trustee”), and U.S. BANK NATIONAL ASSOCIATION, in its capacity as collateral agent for the Secured Parties (as defined below) (and its successors under the Indenture, in such capacity, the “Collateral Agent”).
TRANSITION SERVICES AGREEMENTTransition Services Agreement • February 1st, 2019 • Egalet Corp • Pharmaceutical preparations • Delaware
This TRANSITION SERVICES AGREEMENT is dated as of January 31, 2019 (this “Agreement”), by and between Iroko Pharmaceuticals, LLC, a Delaware limited liability company (the “Company”), and Egalet US, Inc., a Delaware corporation (“Buyer”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 1st, 2019 • Egalet Corp • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of January 31, 2019, by and among Egalet Corporation, a Delaware corporation (the “Company”), and Iroko Pharmaceuticals Inc., a business company incorporated in the British Virgin Islands (registration number 1732699) (the “Stockholder”).
LOCK-UP LETTEREgalet Corp • February 1st, 2019 • Pharmaceutical preparations
ROYALTY RIGHT AGREEMENTRoyalty Right Agreement • February 1st, 2019 • Egalet Corp • Pharmaceutical preparations • New York
FORM OF COMMON STOCK PURCHASE WARRANT(1) EGALET CORPORATIONCommon Stock Purchase Warrant • February 1st, 2019 • Egalet Corp • Pharmaceutical preparations • Delaware
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from time to time after the date hereof (the “Initial Exercise Date”), to subscribe for and purchase from Egalet Corporation, a Delaware corporation (the “Company”), [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
